Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that the latest developments of Genedata Screener® will be shown in the European Laboratory Robotics Interest Group (ELRIG) 7th Annual Drug Discovery Conference. An ELRIG poster session will present a collaborative project with Bayer Pharma, which resulted in “A Novel Data Processing Workflow for Efficient Analysis of Large-Scale Thermofluor Assays.” Genedata Screener will also demonstrate its Compound Synergy and High Content Screening extensions during the ELRIG conference in Manchester, England (Booth F; Central Convention Centre; September 3-4).
The latest enhancements to Genedata Screener strengthen its capabilities as a premier data analysis platform for label-free technologies, in particular, enabling rapid assessment of a protein’s thermal stability under a variety of conditions. Using Genedata Screener, pharmaceutical companies can scale-up thermal shift assays and integrate them into existing screening data analysis workflows, reducing data analysis time from days to hours.
Thermal Shift Analysis Goes High-Throughput with Analysis Time Reduced by 80%
The Thermofluor assay, also referred to as Thermal Shift Analysis (TSA) or Differential Scanning Fluorimetry (DSF), is becoming widely-used for diverse applications in drug discovery, including: selection of suitable formulations for therapeutic antibodies; evaluation of additives and ligands for (co-) crystallization experiments; and identification of small molecule modulators of soluble targets and characterization of their binding mode. To run TSA in high-throughput, data analysis software must enable fast and accurate processing of melting curves without time-consuming manual reviews. Genedata Screener uniquely provides these capabilities for TSA in high-throughput mode.
Genedata Screener helps pharmaceutical companies realize the full value of label-free technologies such as TSA. It has been shown to effectively eliminate time-consuming and inaccurate manual processes by automatically processing and synoptically compiling results. Specific quality metrics highlight curves requiring review and direct visual access to curves enables instantaneous curve analysis. Its flexible and accurate data analysis platform can scale from the smallest datasets to thousands of plates in 96-, 384- and 1536-well formats with full time/temperature resolution. In TSA/DSF experiments, Genedata Screener visualization capabilities help to optimize the temperature window by enabling scientists to review overlays of hundreds of melting curves.
Genedata Screener provides a single platform for capturing, analyzing, and managing all types of screening data. It reduces data processing times by upwards to 80% and integrates with any plate-based instrument to support screening at all throughputs, as well as High Content -, Ion Channel -, and Label-free screening technologies. Genedata Screener also allows detailed analyses of cell sub-population changes and compound synergy effects, giving researchers a standardized platform on which they can efficiently visualize and explore compound combinations at unprecedented processing speed and with unsurpassed result quality.
“More than half of the top 25 pharmaceutical companies already rely on Genedata Screener to support a wide variety of plate-based screening technologies, making it the platform of choice for all types of screening data analysis,” said Dr. Othmar Pfannes, CEO of Genedata. “With the latest developments, we demonstrate our commitment to continuously invest in supporting new technologies, which ultimately increases the ROI on Genedata Screener for our customers.”
ELRIG Editorial Note: Genedata Poster Session: September 3 - 4:00 pm - 5:00pm CET. “A Novel Data Processing Workflow for Efficient Analysis of Large-Scale Thermofluor Assays” by Stephan Steigele1*°, Jörg Weiske2*, Stephan Heyse1, and Amaury Fernández-Montalván2° (1Genedata AG, Basel, Switzerland, 2Bayer Pharma AG, Berlin, Germany). To schedule a briefing, contact email@example.com.
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial, and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US. www.genedata.com
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.